Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale | Eli Lilly and Company

Eli Lilly & Co. reported data from obesity drug trials at ObesityWeek 2026. EloraTZP showed 23.3% weight loss at 28 weeks, 60% of patients achieved non-obese BMI at 48 weeks, and 77% reached normal blood glucose levels. Zepbound reduced BMI by 21.4% at 72 weeks in teens. Both drugs improved quality of life. Lilly also claimed retatrutide outperformed Novo Nordisk's Ozempic in weight reduction and blood sugar control.

Eli Lilly (NYSE:LLY) presented obesity and diabetes drug trial results at ObesityWeek 2026. EloraTZP showed 23.3% weight loss and 2.9% A1C reduction. Retatrutide reduced sleep apnea events by 60.6% and knee osteoarthritis pain by 73.1%. Zepbound reduced adolescent BMI by 21.4%. Foundayo users found it convenient. Eloralintide reduced food cravings and alcohol consumption.

Eli Lilly (LLY) will present new data on its obesity treatments at ObesityWeek 2026. Phase 2 results showed EloraTZP, a combination of eloralintide and tirzepatide, achieved significant weight loss and A1C improvements. Retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in Phase 3 trials. Foundayo, a GLP-1 pill, was reported as easy to use in a real-world evidence study.

Eli Lilly's oral obesity drug, Orforglipron, received approval in China, competing with Novo Nordisk's Wegovy and other treatments. Lilly's shares rose 1.2% in premarket trading. Novo's shares also increased over 2%. Analysts expect Novo's pill to outperform Lilly's due to superior weight loss results. China's obesity drug market is projected to grow significantly.

Eli Lilly (LLY) began construction on a $3.5 billion plant in Pennsylvania for obesity drugs, including retatrutide, expected to launch by 2031. The company also secured China approval for its weight-loss pill, orforglipron. Lilly's capex rose to $7.84 billion in 2025, but free cash flow reached $8.97 billion in 2023. The company's revenue nearly doubled from 2023 to 2025, with analysts expecting further growth.

China approved Eli Lilly's GLP-1 weight-loss pill, Muyouda, for overweight or obese adults with related conditions. The drug, already approved in the U.S., is the first oral GLP-1 treatment in China, beating competitors like Novo Nordisk. China's weight-loss market is expanding, with 630 million adults projected to be overweight or obese by 2050, according to a 2025 study in The Lancet.